## **Product** Data Sheet

## AKR1C3-IN-9

Cat. No.:HY-152188CAS No.:2924824-43-9Molecular Formula: $C_{20}H_{20}N_2O_4$ Molecular Weight:352.38

Target: Aldose Reductase

Pathway: Metabolic Enzyme/Protease

Storage: Powder -20°C 3 years
In solvent -80°C 6 months

-20°C 1 month

## SOLVENT & SOLUBILITY

In Vitro

DMSO: 83.33 mg/mL (236.48 mM; ultrasonic and warming and heat to 60°C)

	Solvent Mass Concentration	1 mg	5 mg	10 mg
Preparing Stock Solutions	1 mM	2.8378 mL	14.1892 mL	28.3785 mL
2.23 22.00.013	5 mM	0.5676 mL	2.8378 mL	5.6757 mL
	10 mM	0.2838 mL	1.4189 mL	2.8378 mL

Please refer to the solubility information to select the appropriate solvent.

In Vivo

- 1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: ≥ 2.08 mg/mL (5.90 mM); Clear solution
- 2. Add each solvent one by one: 10% DMSO >> 90% corn oil Solubility: ≥ 2.08 mg/mL (5.90 mM); Clear solution

## **BIOLOGICAL ACTIVITY**

Description	AKR1C3-IN-9 is a selective inhibitor of <u>Aldo-keto Reductase</u> 1C3 (AKR1C3) with an IC <sub>50</sub> value of 8.92 nM. AKR1C3-IN-9 significantly reverses the <u>Doxorubicin</u> (HY-15142A) (DOX) resistance in a resistant breast cancer cell line <sup>[1]</sup> .
IC <sub>50</sub> & Target	IC50: 8.92 nM (AKR1C3) <sup>[1]</sup>
In Vitro	AKR1C3-IN-9 (compound 24) (10-100 $\mu$ M; 72 h and 96 h) results weak antiproliferative effect up to 100 $\mu$ M in all three breast cancer cell lines (MDA-MB-231, MCF-7) <sup>[1]</sup> . AKR1C3-IN-9 (10 $\mu$ M, 25 $\mu$ M, and 50 $\mu$ M; 72 h) synergistically inhibits the proliferation of MCF-7 cell with 10-50 $\mu$ M DOX <sup>[1]</sup> .

AKR1C3-IN-9 (10  $\mu$ M, 25  $\mu$ M, and 50  $\mu$ M; 72 h) synergistically inhibits the proliferation of MCF-7 cell with 10-50  $\mu$ M DOX<sup>[-1]</sup>. AKR1C3-IN-9 (10  $\mu$ M; 8 d) synergistically inhibits the proliferation, clonogenic survival of MCF-7/DOX cell line, thus restores the sensitivity to DOX<sup>[1]</sup>.

 $\label{eq:mce} \mbox{MCE has not independently confirmed the accuracy of these methods. They are for reference only.}$ 

247:115013.	t highly potent and specific A	.KRIC3 inhibitors to restore the c	nemosensitivity of drug-resistant brea	ast cancer. Eur J Med Chem. 2022 Dec
	Caution: Product has r	ot been fully validated for mo	edical applications. For research	use only
	Tel: 609-228-6898	Fax: 609-228-5909	E-mail: tech@MedChemExp	
		L Deer Park Dr, Suite Q, Monmo		

Page 2 of 2 www.MedChemExpress.com